Health Disparities in Hematologic Malignancies: From Genes to Outreach Weill Cornell Medicine; Belfer Auditorium June 6-7, 2025

Day 1 - Friday June 6, 2025

7:30 am	Registration and Breakfast:
8:00 am	Opening remarks
• 8:05	Esther N. Mune, Ph.D. Lymphoma survivor- Emory, Atlanta
8:20- 10:05 am	Session 1: The impact of germline variants and genomic abnormalities
• 8:20	Catherine Marinac, Ph.D. Dana Farber Cancer Institute, Boston, MA Screening for monoclonal gammopathies in a high-risk population: an update on the promise study
• 8:35	Lyndon Mitnaul, Ph.D. Regeneron Pharmaceuticals, Inc., Tarrytown, New York Regeneron Genetics Center: Inclusive Genomics Research Through the Together for CHANGE™ Initiative
• 8:50	Maureen Murphy, Ph.D. Wistar Institute, Philadelphia, PA African-specific genetic variants in TP53 contribute to increased cancer risk
• 9:05	Discussion leader: Michelle Hildebrandt, Ph.D. The University of Texas, MD Anderson Cancer Center
9:50 -10:15 am	Coffee Break
10:15-11:45 pm	Session 2: Prognostic and therapeutic implications of the molecular landscape- Part A
• 10:15	Aaron Viny, M.D. Columbia University, New York, NY High-risk clinical and molecular features hallmark Hispanic patients with acute promyelocytic leukemia
• 10:30	Wendy Cozen, D.O. University of California, Irvine, CA Ethnic differences in MGUS isotypes and associations with immune biomarkers: First reports from the multi-cohort study of MGUS determinants
• 10:45	Sandeep Dave, M.D. Duke University, Durham, NC Genetic origins of adverse outcomes in African Americans with lymphoma

• 11:00	Rosalie Griffin Ph.D.
	The University of Texas, MD Anderson Cancer Center
	Genomic diversity reveals CLL risk and prognostic factors
• 11:15	Discussion leader: Wendy Cozen, D.O.
• 11.15	University of California, Irvine, CA (30 min call to action-discussion)
	Chiversity of Camorina, II vinie, Cr. (35 min can to action alsoassion)
11:45 pm	Lunch
1:00-3:00 pm	Session 3: The impact of social determinants of health on outcomes
• 1:00	Helen Ma, M.D.
	UC Irvine; A Long Beach Healthcare System in Long Beach, CA
	Veteran's Health: The Connection Between Military Exposure and Lymphoma
• 1:15	Alison Walker, M.D.
1.15	Moffit Cancer Center, Tampa, FL
	When Access Determines Outcomes: AML Survival in Underserved Populations
• 1:30	Theresa Keegan, Ph.D.
1.30	University of California Davis School of Medicine, Sacramento, CA
	Sociodemographic disparities in outcomes among Hodgkin lymphoma patients
• 1:45	Oreofe Odejide, M.D.
	Dana Farber Cancer Institute, Boston, MA
	Impact of Insurance on End-of-Life Care Among Older Adults with Blood Cancers
• 2:00	Wellington Fernandes da Silva, M.D., Ph.D.
	Instituto do Cancer do Estado de São Paulo (ICESP), Faculdade de Medicina da Universidade de
	Sao Paulo, Sao Paulo, Brazil
	Management and outcomes of ALL in resource-constrained settings
• 2:15	Discussion leader: Warren Fingrut, M.D.
	The University of Texas MD Anderson Cancer Center
3:00 -3:25 pm	Coffee Break
3:20-3:50 pm	Voyneto
5.20-5.50 pm	Keynote:
• 3:20	Elisa Weiss, Ph.D.
	Sr. Vice President of Education, Services & Health Research, The Leukemia & Lymphoma
	Society
	No Magic Bullet: A Multi-Pronged Approach to Increasing Equitable Access to Cancer Clinical
3:50-5:00 pm	Trials Session 4: Developing strategies to increase community representation in clinical enrollment
3.30-3.00 pm	Session 4. Developing strategies to increase community representation in chinical enrollment
• 3:50	Shalini Hede, Pharm.D.
3.33	Medical Affairs Executive Director, Genentech; Hillsborough, NJ
	Five Data-Informed Principles for Advancing Inclusive Research (AIR) in Clinical Trials

5:45-7:45pm	Poster Session and Happy Hour
	The University of Texas MD Anderson Cancer Center
	Discussion Leader: Luis Malpica, M.D.
	Lymphoma survivor & LLS Patient navigator
	Jonathan Guerrero_ Patient Advocate
	Lymphoma Survivor- NYU Langone
	Ms. Idatiu Diallo
5:10 -5:45	Patient Advocacy Session
	New York University Langone Hospital, Brooklyn, NY
	Discussion leader: Oscar Lahoud, M.D.
	University of Texas Health Science Center, San Antonio, TX
	Enrique Diaz, M.D.
	Program
• 4:20	Nina Logan, M.D. Senior Director, Research & Clinical Programs, Leukemia & Lymphoma Society: IMPACT
	Breet to patient red aitment may exact bate anaerrepresentation in cancer research
	Washington University School of Medicine, St. Louis, MO Direct-to-patient recruitment may exacerbate underrepresentation in cancer research
• 4:05	Mark Fiala, Ph.D., MSW

Day 2 - Saturday, June 7, 2025

8:00- 8:30 am	Registration and Breakfast
8:30- 8:30 am	Session 5: Prognostic and therapeutic implications of the molecular landscape- Part B
• 8:30	Jatinder Lamba, Ph.D.
	University of Florida College of Pharmacy, Gainesville, FL Can PGx based personalization mitigate outcome disparities in Hematological Malignancies?
• 8:45	H. Leighton Grimes, Ph.D. Cincinnati Children's, Hospital, Cincinnati, OH A genetic-genomics dissection of ancestry associated outcomes in acute myeloid leukemia.
• 9:00	Lawrence Boise, Ph.D. Emory University School of Medicine, Atlanta, GA Defining the landscape of structural alterations in African American multiple myeloma
• 9:15	Nancy Gillis-Johnson, Pharm.D., Ph.D. Moffit Cancer Center, Tampa, FL Racial and Ethnic Differences in Clonal Hematopoiesis, Tumor Markers, and Outcomes of Patients with Hematologic Malignancies

• 9:30	Discussion leader: Monica Guzman, Ph.D. Weill Cornell Medicine
10:15 -10:35 am	Coffee Break
10:35- 12:00 pm	Session 6: The burden of lymphoproliferative disorders in Latin America & lower-middle-income countries
• 10:35	Carlos Chiattone, M.D. Faculdade de Ciências Médicas da Santa Casa de São Paulo, Brazil Treatment and outcomes of lymphoma patients in Brazil and LATAM
• 10:50	Cristobal Frutos M.D. Instituto de Previsión Social, Asuncion, Paraguay Stem cell Transplants in Latin America: mapping, sequencing and treating myeloid malignancies
• 11:05	Robert Baiocchi, M.D. Ohio State University Comprehensive Cancer Center, Columbus, OH Profiling the CpG methylation patterns of Epstein-Barr virus DNA in lymphoma patients from Ethiopia
• 11:20	Daniel Enriquez- Vera, MD. Kagoshima University, Sakuragaoka, Kagoshima, Japan Disparities and diversity of HTLV-1 infection and ATL in Peru
• 11:35	Discussion leader: Guilherme Duffles Amarante, M.D. Faculdade de Ciências Médicas da Santa Casa de São Paulo, Brazil
12:00 pm	Lunch
1:15-1:35 pm	Session 7 P <u>roject Highlight</u> : The Leukemia & Lymphoma Society's Specialized Center of Research (SCOR) program
	Jean Koff, M.D., M.S. Emory Winship Cancer Institute, Atlanta, GA Translating molecular profiles into treatment approaches to target disparities in lymphoma
1:35 – 2:50 pm	Session 8: Developing a funding strategy to address disparities
• 1:35 pm	Meghan Gutierrez Chief Executive Officer, Lymphoma Research Foundation
• 1:45 pm	Lore Gruenbaum, Ph.D. Sr. Vice President and Chief Scientific Officer, The Leukemia & Lymphoma Society
• 1:55 pm	Patricia Frustace Senior Director, Awards & Diversity Programs, American Society of Hematology

• 2:05 pm	Deirdra R. Terrell, Ph.D. University of Oklahoma Health Sciences Center; ASH MRI Program	
• 2:15 pm	Discussion leader: Christopher Flowers, M.D., M.S., FASCO The University of Texas, MD Anderson Cancer Center	
3:00 -3:15 pm	Coffee Break	
3:15 – 4:15 pm	Keynote:	
	Kelou Fox, Ph.D. University of California San Diego, San Diego, CA Robin Hood Genomics: Sequencing for Sovereignty	
4:15 -4:20 pm	Closing Remarks	
4:20 pm	Adjourn	